Nykode Therapeutics announces clinical collaboration with MSD

Published: Tue Dec 06 2022

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer

Nykode Therapeutics ASA today announced that it has entered into a clinical collaboration and supply agreement with MSD, to evaluate Nykode’s wholly-owned lead candidate, VB10.16, in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a Phase 1/2a trial in patients with HPV16-positive head and neck cancer.

Read more